Results of a Prospective Randomized Trial Comparing Standard Dose Neuraxis Irradiation (3,600 cGy/20) with Reduced Neuraxis Irradiation (2,340 cGy/13) in Patients with Low-Stage Medulloblastoma

Abstract

In patients with newly diagnosed medulloblastoma considered to have a good prognosis on the basis of low T stage, minimal residual tumor after at least subtotal resection, and no evidence of dissemination after thorough evaluation, there is an increased risk of early relapse associated with lowering the dose of neuraxis radiation from 3,600 cGy in 20 fractions to 2,340 cGy in 13 fractions.